Yang Lei Lei, Zhou Feng, Xu Qi, Ye Ting, Xiong Hong
Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology Ophthalmology, Wuhan 430030, China.
Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Ultrasound Diagnosis Department, Wuhan 430030, China.
Evid Based Complement Alternat Med. 2022 Aug 18;2022:7327609. doi: 10.1155/2022/7327609. eCollection 2022.
The incidence of neovascular eye disease is increasing year by year, seriously threatening human vision health and becoming an urgent public health problem. Tongmai fuming decoction as an experienced prescription can treat ischemic eye disease.
To investigate the therapeutic effect of Tongmai fuming decoction combined with anti-VEGF therapy on neovascular ophthalmopathy.
52 patients (62 eyes) with neovascular ophthalmopathy who met the inclusion criteria from January 2018 to July 2020 were randomly divided into the control and observation groups. The control group was given an intravitreal injection of antivascular endothelial growth factor (VEGF) drugs once a day combined with on-demand treatment. The observation group was treated with traditional Chinese medicine Tongmai fuming decoction in addition to the treatment of anti-VEGF drugs. The best-corrected visual acuity (BCVA) was examined before and after treatment, and optical coherence tomography angiography (OCTA) was used to examine the mean retinal thickness and neovascularization in the macular area. Patients were followed for one year and the number of anti-VEGF injections was recorded.
After treatment, the average thickness of BCVA and macular retina in the two groups significantly improved. The BCVA of the control group was 0.59 ± 0.39 3 months after treatment, and that of the experimental group was 0.42 ± 0.25 3 months after treatment. The average thickness of the macular retina in the control group was 304.8 ± 79.7 3 months after treatment, and that in the experimental group was 267.7 ± 64.6 3 months after treatment; The average number of injections of anti-VEGF therapy in the control group was 2.32 ± 1.15 times, and that in the experimental group was 1.74 ± 0.76 times. There was a significant difference between the two groups.
Tongmai fuming decoction and anti-VEGF therapy have a synergistic effect in the treatment of neovascular ophthalmopathy, which can reduce the treatment times of anti-VEGF drugs.
新生血管性眼病的发病率逐年上升，严重威胁人类视力健康，成为亟待解决的公共卫生问题。通脉复明汤作为经验方，可治疗缺血性眼病。
探讨通脉复明汤联合抗VEGF治疗对新生血管性眼病的疗效。
选取2018年1月至2020年7月符合纳入标准的52例（62只眼）新生血管性眼病患者，随机分为对照组和观察组。对照组给予玻璃体内注射抗血管内皮生长因子（VEGF）药物，每日1次，并根据需要进行治疗。观察组在抗VEGF药物治疗的基础上，加用中药通脉复明汤治疗。治疗前后检查最佳矫正视力（BCVA），采用光学相干断层扫描血管造影（OCTA）检查黄斑区视网膜平均厚度及新生血管情况。随访患者1年，记录抗VEGF注射次数。
治疗后，两组患者的BCVA及黄斑视网膜平均厚度均显著改善。治疗3个月后，对照组BCVA为0.59±0.39，试验组为0.42±0.25。治疗3个月后，对照组黄斑视网膜平均厚度为304.8±79.7，试验组为267.7±64.6；对照组抗VEGF治疗的平均注射次数为2.32±1.15次，试验组为1.74±0.76次。两组间差异有统计学意义。
通脉复明汤与抗VEGF治疗新生血管性眼病具有协同作用，可减少抗VEGF药物的治疗次数。
